IceCure Medical (ICCM) names David Salton to board as independent director

Rhea-AI Filing Summary

IceCure Medical Ltd. reported a Board change. Vincent Chun Hung Chan resigned as a director, effective August 14, 2026, and the company stated his resignation was not related to any disagreement regarding operations, policies or practices. The Board appointed David Salton as an independent Class II director until the 2027 annual general meeting of shareholders.

Salton will serve on the Compensation Committee, the Audit Committee and Financial Statement Examination Committee. IceCure expects to enter into its standard indemnification and exemption agreement with him, on the same terms as for other directors and executive officers, and disclosed that there are no related party transactions involving him requiring disclosure under Item 7.B of Form 20-F. His background includes CEO roles at medical technology start-ups and multiple prior independent directorships.

Key Figures

Effective date of resignation: August 14, 2026 Report month: August 2026 AGM reference year: 2027

3 metrics

Effective date of resignation August 14, 2026 Date Vincent Chun Hung Chan’s resignation from the Board becomes effective

Report month August 2026 Month covered by the foreign private issuer report

AGM reference year 2027 Year of the annual general meeting through which David Salton will serve as Class II director

Key Terms

independent director, Class II director, Compensation Committee, Audit Committee and Financial Statement Examination Committee, +2 more

6 terms

independent director regulatory

"the Board appointed Mr. David Salton to serve as an independent director on the Board"

An independent director is a member of a company's board of directors who is not involved in the company's day-to-day operations and has no significant relationships with the company that could influence their judgment. Their role is to provide unbiased oversight and ensure the company is managed in the best interests of all shareholders. This helps build trust and confidence among investors by promoting transparency and accountability.

Class II director regulatory

"serve as an independent director on the Board and as a Class II director until the annual"

A class II director is a member of a company’s board who belongs to one of several staggered groups of directors, each group standing for election in different years. For investors, this matters because staggered terms slow wholesale board turnover—like rotating members of a neighborhood committee—making sudden changes in control or strategy harder and affecting how quickly shareholders can influence corporate direction.

Compensation Committee financial

"Mr. Salton will also serve on the Company’s Compensation Committee and Audit Committee"

A compensation committee is a group within a company's leadership responsible for setting and reviewing how much top executives and employees are paid, including salaries, bonuses, and benefits. It matters to investors because fair and effective pay decisions can influence a company's performance, leadership motivation, and overall governance, helping ensure that the company’s management is aligned with shareholders’ interests.

Audit Committee and Financial Statement Examination Committee financial

"serve on the Company’s Compensation Committee and Audit Committee and Financial Statement Examination Committee"

indemnification and exemption agreement regulatory

"enter into its standard form of indemnification and exemption agreement with Mr. Salton"

related party transactions financial

"There are no related party transactions involving Mr. Salton required to be disclosed"

Transactions between a company and people or entities that have close ties to it—such as executives, board members, major shareholders, family members, or related companies—where the parties are not independent. These deals matter to investors because they can create conflicts of interest or hide favorable terms that distort a company’s true profits and risks; think of it like a business buying or selling to a family member instead of using the open market, which can lead to biased prices or undisclosed obligations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 08/11/2026 - 04:15 PM Accepted by SEC EDGAR 08/11/2026 - 04:15 PM Learn about SEC filing dates

FAQ

What board change did IceCure Medical (ICCM) report in August 2026?

IceCure Medical reported that Vincent Chun Hung Chan resigned from its Board, effective August 14, 2026. The company stated the resignation was not related to any disagreement on operations, policies or practices, and concurrently appointed a new independent director.

Who was appointed to IceCure Medical’s (ICCM) Board and how long will he serve?

The Board appointed David Salton as an independent Class II director. He will serve until the company’s annual general meeting of shareholders to be held in 2027, subject to the usual corporate governance framework and shareholder processes.

What board committees will David Salton serve on at IceCure Medical (ICCM)?

David Salton will serve on IceCure Medical’s Compensation Committee and its Audit Committee and Financial Statement Examination Committee. These roles involve oversight of executive pay, financial reporting processes, and examination of financial statements.

Did IceCure Medical (ICCM) report any disagreement behind Vincent Chan’s resignation?

No. IceCure Medical stated that Vincent Chun Hung Chan’s resignation from the Board was not related to any disagreement with the company on matters relating to its operations, policies, or practices, indicating a non-dispute departure.

Will IceCure Medical (ICCM) enter into an indemnification agreement with David Salton?

Yes. IceCure Medical expects to enter into its standard indemnification and exemption agreement with David Salton. The terms will match those in indemnification agreements previously entered into with the company’s other directors and executive officers.

Are there any related party transactions involving new director David Salton at IceCure Medical (ICCM)?

The company stated there are no related party transactions involving David Salton that are required to be disclosed under Item 7.B of Form 20-F, indicating no such disclosable relationships at this time.

 UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of August 2026 (Report No. 2)

Commission File Number: 001-40753

ICECURE MEDICAL Ltd.

(Translation of registrant’s name into English)

7 Ha’Eshel St., PO Box 3163

Caesarea, 3079504 Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F      ☐ Form 40-F

CONTENTS

On August 11, 2026, IceCure Medical Ltd. (the “Company”) announced that Mr. Vincent Chun Hung Chan resigned as a member of the Board of Directors (the “Board”), effective August 14, 2026. Mr. Chan’s resignation was not related to any disagreement with the Company on any matter relating to its operations, policies or practices.

In his place, the Board appointed Mr. David Salton to serve as an independent director on the Board and as a Class II director until the annual general meeting of shareholders to be held in 2027. Mr. Salton will also serve on the Company’s Compensation Committee and Audit Committee and Financial Statement Examination Committee

In connection with this appointment, the Company expects to enter into its standard form of indemnification and exemption agreement with Mr. Salton on the same terms as the indemnification agreements previously entered into between the Company and each of its directors and executive officers. There are no related party transactions involving Mr. Salton required to be disclosed under Item 7.B of Form 20-F.

Mr. David Salton has served as the Chief Executive Officer of AnchorMesh Ltd., a start-up company developing orthopedic implants since July 2024. Prior to that, he served as Chief Executive Officer, President, director of Virility Medical Ltd., a start-up company, developing consumer medical devices. From May 2022 to February 2024, he served as an independent director of SHL Telemedicine Ltd. (Nasdaq:SHLT). From February 2016 to February 2025, Mr. Salton served as an independent director of ARAN Research & Development (1982) Ltd. (TASE: ARAN). Since December 2014, he has served as an independent director at InterCure Inc. (Nasdaq: INCR). Mr. Salton holds a Bachelor’s of Science degree in economics and management from the Technion - Israel Institute of Technology. 

This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Company’s Registration Statements on Form F-3  (File Nos. 333-297030, 333-290046 and 333-258660) and Form S-8 (File Nos. 333-270982, 333-264578, 333-262620 and 333-281587), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this Report of Foreign Private Issuer on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	IceCure Medical Ltd.
Date: August 11, 2026	By:	/s/ Eyal Shamir
		Eyal Shamir
		Chief Executive Officer

2